Eco
Epipen & Monopoly
Skip To Content
Dashboard
  • Login
  • Dashboard
  • Calendar
  • Inbox
  • History
  • Help
Close
  • My Dashboard
  • Eco
  • Assignments
  • Epipen & Monopoly
  • Home
  • Modules
  • Discovery Education
  • Google Drive
  • DeltaMath
  • Lucid (Whiteboard)
  • DBQ Online
  • Canva for Education
  • Lumio

Epipen & Monopoly

  • Due No Due Date
  • Points 0
  • Submitting a text entry box

monop2.PNG

Mylan pharmaceutical company has a virtual monopoly on EpiPens after a voluntary recall felled their only competitor*, Sanofi’s Auvi-Q, over possible dosage miscalibrations. It’s not the drug being delivered that brings the bucks, though—epinephrine’s a cheap generic. The cost trickery is in the delivery system, the Mylan EpiPen.

The EpiPen’s been around since 1977, but Mylan acquired the autoinjector—which precisely calibrates the epinephrine dosage—in 2007. The patient now pays about 400% more for this advantage to receive a dollar’s worth of the lifesaving drug: EpiPens were about $57 when Mylan acquired it. Today, it can empty pockets of $500 or more in the U.S. (European nations take a different approach to these things).

Why can Mylan charge so much for EpiPens? Give two reasons.

0
Please include a description
Additional Comments:
Rating max score to > pts
Please include a rating title

Rubric

Find Rubric
Please include a title
Find a Rubric
Title
You've already rated students with this rubric. Any major changes could affect their assessment results.
 
 
 
 
 
 
 
     
Can't change a rubric once you've started using it.  
Title
Criteria Ratings Pts
This criterion is linked to a Learning Outcome Description of criterion
threshold: 5 pts
Edit criterion description Delete criterion row
5 to >0 pts Full Marks blank
0 to >0 pts No Marks blank_2
This area will be used by the assessor to leave comments related to this criterion.
pts
  / 5 pts
--
Additional Comments
Total Points: 5 out of 5